Evidence map›Paper›PMID 41118217›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Mutant p53 regulates cancer cell invasion in complex three-dimensional environments through mevalonate pathway-dependent Rho/ROCK signaling.

Asja Guzman, Tatsuya Kawase, Alexander J Devanny, Gizem Efe, Raúl Navaridas, Karen Yu, Kausik Regunath, Iris G Mercer, Rachel C Avard, Rafaela Muniz de Queiroz and 3 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Asja GuzmanDepartment of Biological Sciences, Columbia University, New York, NY 10027.
Tatsuya KawaseAstellas Pharma Inc., Tsukuba-shi, Ibaraki 305-8585, Japan.ORCID 0000-0003-2253-2238
Alexander J DevannyDepartment of Chemistry, Columbia University, New York, NY 10027.
Gizem EfeHerbert Irving Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032.
Raúl NavaridasHerbert Irving Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032.
Karen YuDepartment of Physics, Columbia University, New York, NY 10027.
Kausik RegunathDepartment of Biological Sciences, Columbia University, New York, NY 10027.
Iris G MercerDepartment of Chemistry, Columbia University, New York, NY 10027.
Rachel C AvardDepartment of Chemistry, Columbia University, New York, NY 10027.
Rafaela Muniz de QueirozDepartment of Biological Sciences, Columbia University, New York, NY 10027.
Anil K RustgiHerbert Irving Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032.
Laura J KaufmanDepartment of Chemistry, Columbia University, New York, NY 10027.
Carol PrivesDepartment of Biological Sciences, Columbia University, New York, NY 10027.ORCID 0000-0003-1846-5562

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
Mutant p53 in Tumorigenesis, Invasion, and MetastasisP01CA291694 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Emily Bernstein · 2025 to 2026
$7.9M
Functions and Activities of p53 and Mdm2 in Normal and Cancer CellsR35CA220526 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI PRIVES, CAROL · 2018 to 2024
$6.0M
HHS | NIH | National Cancer Institute (NCI) F31CA275369-02HHS | NIH | National Cancer Institute (NCI) P01-CA098101NCI NIH HHS P01 CA291694NCI NIH HHS P30 CA013696NCI NIH HHS R35 CA220526
6 · The paper itself

Abstract

Certain

Indexed as

Mevalonic AcidNeoplasmsrhoA GTP-Binding Proteinrho-Associated KinasesSignal TransductionTumor Suppressor Protein p53Cell Line, TumorCell MovementExtracellular MatrixGain of Function MutationHumansMutationNeoplasm InvasivenessMevalonic AcidrhoA GTP-Binding ProteinRHOA protein, humanrho-Associated KinasesTP53 protein, humanTumor Suppressor Protein p53IDI-1invasionmevalonate pathwaymutant p53Rho/ROCK signaling

Identifiers

PMID41118217
PMCPMC12582287

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.